IP Library Granted Patent US 8,299,079
Granted Patent B2
US 8,299,079 · App. 12/973,479 · Granted Oct 30, 2012

Preparations and methods for ameliorating or reducing presbyopia

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,299,079
App. No.
12/973,479
Granted
Oct 30, 2012
Kind
B2
Abstract

This application relates to the use of one or more parasympathomimetic drugs in combination with one or more alpha agonists to create optically beneficial miosis to, for example, temporarily treat presbyopia. The invention provides a pharmaceutical preparation comprising a therapeutically effective amount of one or more parasympathomimetic drugs or cholinesterase inhibitors, or a pharmaceutically acceptable salt thereof, in combination with one or more alpha agonists or antagonists, or a pharmaceutically acceptable salt thereof. The invention further provides for a method for treating, ameliorating or reducing presbyopia of a patient having an eye, comprising administering to said eye a pharmaceutically effective amount of the ophthalmic preparation.

Claims (6)

1. A method for ameliorating or reducing presbyopia of a patient having an eye, comprising administering to said eye a therapeutically effective amount of an ophthalmic topical preparation comprising a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof, in an amount of 0.25-1.0% and brimonidine, or a pharmaceutically acceptable salt thereof in an amount of 0.05-0.2%.

2. The method of claim 1 , wherein pilocarpine is present in an amount of 1% and brimonidine is present in an amount of 0.20%.

3. A method of producing ocular miosis in a subject under normal light conditions which comprises administering to the subject an amount of an ophthalmic preparation comprising a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof, in an amount of 0.25-1.0% and brimonidine, or pharmaceutically acceptable salts thereof, in an amount of 0.05-0.2% effective to produce ocular miosis.

4. A method of ameliorating, reducing or eliminating dimness of vision of a patient having an eye comprising administering to said eye a therapeutically effective amount of an ophthalmic preparation comprising a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof, in an amount of 0. 25-1.0% and brimonidine or a pharmaceutically acceptable salt thereof in an amount of 0.05-0.2%.

5. A method of improving focus and/or correcting refractive errors of a patient having an eye comprising administering to said eye a therapeutically effective amount of an ophthalmic preparation comprising a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof, in an amount of 0. 25-1.0% and brimonidine, or pharmaceutically acceptable salts thereof in an amount of 0.05-0.2%.

6. A method of treating presbyopia in a patient in need of treatment thereof comprising administering an effective amount of an ophthalmic topical preparation comprising a therapeutically effective amount pilocarpine, or a pharmaceutically acceptable salt thereof, in an amount of 0.25-1.0% and brimonidine, or a pharmaceutically acceptable salt thereof in an amount of 0.05-0.2%. to a single eye of a patient thereby leaving the other eye untreated.

Assignments (5)
SECURITY INTEREST Recorded Jan 9, 2026
From: TENPOINT THERAPEUTICS HOLDING LIMITED; TENPOINT THERAPEUTICS LIMITED; VISUS THERAPEUTICS, INC.; TENPOINT THERAPEUTICS INC.
To: HERCULES CAPITAL, INC., AS AGENT
Reel/Frame 073417/0714 →
RELEASE OF SECURITY INTEREST REEL 066839, FRAME 0679 Recorded Dec 31, 2025
From: LSP 6 HOLDING C.V., AS COLLATERAL AGENT
To: VISUS THERAPEUTICS, INC.
Reel/Frame 074145/0450 →
SECURITY INTEREST Recorded Mar 20, 2024
From: VISUS THERAPEUTICS, INC.
To: LSP 6 HOLDING C.V., AS COLLATERAL AGENT
Reel/Frame 066839/0679 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 22, 2020
From: HEK DEVELOPMENT, LLC
To: VISUS THERAPEUTICS, INC.
Reel/Frame 052733/0106 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 5, 2013
From: KAUFMAN, HERBERT F.
To: HEK DEVELOPMENT, LLC
Reel/Frame 029753/0980 →